CN116509969A - Traditional Chinese medicine composition for treating cow clinical type mastitis and application thereof - Google Patents
Traditional Chinese medicine composition for treating cow clinical type mastitis and application thereof Download PDFInfo
- Publication number
- CN116509969A CN116509969A CN202310394287.XA CN202310394287A CN116509969A CN 116509969 A CN116509969 A CN 116509969A CN 202310394287 A CN202310394287 A CN 202310394287A CN 116509969 A CN116509969 A CN 116509969A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- chinese medicine
- medicine composition
- mastitis
- dandelion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 60
- 208000004396 mastitis Diseases 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 claims abstract 2
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 25
- 241000245665 Taraxacum Species 0.000 claims description 24
- 244000062241 Kaempferia galanga Species 0.000 claims description 23
- 235000013421 Kaempferia galanga Nutrition 0.000 claims description 23
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims description 23
- 244000153955 Reynoutria sachalinensis Species 0.000 claims description 23
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 22
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 22
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 22
- 240000009022 Smilax rotundifolia Species 0.000 claims description 22
- 235000003205 Smilax rotundifolia Nutrition 0.000 claims description 22
- 241001061264 Astragalus Species 0.000 claims description 21
- 235000006533 astragalus Nutrition 0.000 claims description 21
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 21
- 235000011477 liquorice Nutrition 0.000 claims description 21
- 210000004233 talus Anatomy 0.000 claims description 21
- 241000007126 Codonopsis pilosula Species 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 16
- 239000002994 raw material Substances 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 7
- -1 spina gleditsiae Chemical compound 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 239000006186 oral dosage form Substances 0.000 claims description 3
- 229940126680 traditional chinese medicines Drugs 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 abstract description 53
- 235000013336 milk Nutrition 0.000 abstract description 40
- 210000004080 milk Anatomy 0.000 abstract description 40
- 239000008267 milk Substances 0.000 abstract description 40
- 230000000694 effects Effects 0.000 abstract description 29
- 230000036407 pain Effects 0.000 abstract description 20
- 208000002193 Pain Diseases 0.000 abstract description 19
- 230000008961 swelling Effects 0.000 abstract description 14
- 208000024891 symptom Diseases 0.000 abstract description 8
- 210000001165 lymph node Anatomy 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 description 44
- 241000699670 Mus sp. Species 0.000 description 20
- 210000000952 spleen Anatomy 0.000 description 13
- 235000013365 dairy product Nutrition 0.000 description 12
- 210000002784 stomach Anatomy 0.000 description 12
- 230000001737 promoting effect Effects 0.000 description 10
- 230000000202 analgesic effect Effects 0.000 description 9
- 210000001082 somatic cell Anatomy 0.000 description 9
- 208000000114 Pain Threshold Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 230000037040 pain threshold Effects 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000036528 appetite Effects 0.000 description 5
- 235000019789 appetite Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000033809 Suppuration Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 230000006651 lactation Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 239000009636 Huang Qi Substances 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 206010024642 Listless Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000017971 listlessness Diseases 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 241000756943 Codonopsis Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- ZDGGJQMSELMHLK-UHFFFAOYSA-N m-Trifluoromethylhippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=CC(C(F)(F)F)=C1 ZDGGJQMSELMHLK-UHFFFAOYSA-N 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 235000019633 pungent taste Nutrition 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- HSTZMXCBWJGKHG-UHFFFAOYSA-N (E)-piceid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-UHFFFAOYSA-N 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010006272 Breast mass Diseases 0.000 description 1
- 206010006298 Breast pain Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010060710 Galactostasis Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000006662 Mastodynia Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038084 Rectocele Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 235000008326 Trichosanthes anguina Nutrition 0.000 description 1
- 244000078912 Trichosanthes cucumerina Species 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N anhydrous n-heptane Natural products CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000010231 banlangen Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002630 limonoids Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 150000002995 phenylpropanoid derivatives Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229960003764 polydatin Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- HSTZMXCBWJGKHG-CUYWLFDKSA-N trans-piceid Polymers O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-CUYWLFDKSA-N 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/483—Gleditsia (locust)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pregnancy & Childbirth (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a traditional Chinese medicine composition for treating cow clinical type mastitis and application thereof, and relates to the technical field of traditional Chinese medicine preparations. The traditional Chinese medicine composition has obvious effects of relieving and eliminating symptoms such as red swelling, heat and pain, unsmooth milk discharge, swelling of lymph nodes on milk and the like of diseased cows, and has higher cure rate on clinical mastitis of cows.
Description
Technical Field
The invention relates to the technical field of animal traditional Chinese medicine pharmacy, in particular to a traditional Chinese medicine composition for treating cow clinical mastitis and application thereof.
Background
Mastitis is a common disease of cows, and the cause of the mastitis is very complex, and is the result of the combined action of the cow body, pathogenic microorganisms and the feeding environment. Mastitis has great influence on dairy cows, beef cattle and yaks, and the annual incidence rate of the mastitis of the dairy cows in China is about 28-62%, wherein the incidence rate of the recessive mastitis is 33.4%, and the incidence rate of the clinical mastitis is about 3-5%. The mastitis not only causes the short-term milk yield of the dairy cows to be reduced and the milk quality to be not up to standard, but also causes the suppuration and gangrene of the dairy cows to lose the milk yield and be eliminated; mastitis can also cause adverse effects such as cow milk secretion reduction, milk spoilage, body temperature rise, listlessness, appetite reduction, calf growth retardation or death caused by refusal of lactation, and the like, and huge economic loss is caused to breeding production.
At present, the clinical treatment of cow mastitis is mainly performed by antibiotics, but bacterial drug resistance is generated. The problems of drug residue, food safety and the like limit the use of antibiotics to a great extent, and the traditional Chinese veterinary drug has the advantages of definite curative effect, environmental protection, no drug resistance, no toxic or side effect and the like, and has become a hotspot for treating diseases such as cow mastitis and the like. In clinical researches on prevention and treatment of cow mastitis by traditional Chinese medicines, the ancient prescription is more, such as dandelion powder, snakegourd fruit powder, zhibasan and the like, has higher clinical effective rate, and shows that the ancient prescription has high research value on the current cow mastitis. However, the action mechanism and the dose-effect relation of the traditional Chinese medicine for preventing and treating cow mastitis are not very clear, so that the implementation effect difference is large when the traditional Chinese medicine is applied to veterinary clinic for preventing and treating cow mastitis. Moreover, clinical studies mainly prevent and treat recessive mastitis, and have few application studies on clinical mastitis, especially acute Linchuan mastitis.
Dominant mastitis is known as "acute mastitis", and is a disease in which the breast is hard, swelling, hot and painful and the female animal refuses to give birth. The pathogenic toxin invades from the nipple or breast wound, and the pathogenic toxin and accumulated milk are mutually combined, so that the milk collaterals are blocked to form a disease. Because of pathogenic toxin accumulation and heat removal, obstruction of collaterals in the breast and milk stagnation, symptoms such as red swelling and pain of the breast, milk spoilage, lactation reduction, body temperature rise, heart beat acceleration, listlessness, appetite reduction and the like appear. It is also known in postnatal lactation of female animals, and is also known in parturient after pregnancy. The traditional Chinese medicine and veterinary medicine generally take the heat-clearing and detoxicating, blood circulation activating and stasis removing, detumescence and stagnation resolving as the treatment principle, and achieve the purpose of treating the mammitis by conditioning various functional indexes of the organism.
In the prior art, no research results of a traditional Chinese medicine prescription specially aiming at the treatment of cow clinical mastitis exist, and the invention aims to provide a traditional Chinese medicine composition for treating the clinical mastitis with symptoms of red swelling and pain of cow breasts, unsmooth milk discharge, swelling of lymph nodes on milk and the like and application thereof.
Disclosure of Invention
(one) solving the technical problems
Aiming at the defects of the prior art, the invention provides a traditional Chinese medicine composition for treating cow clinical mastitis and application thereof, wherein the traditional Chinese medicine composition has the effects of detumescence, acesodyne, clearing heat and detoxicating, and promoting qi circulation to remove masses, has better treatment effect on cow clinical mastitis, and has obvious effects of relieving and eliminating symptoms such as red swelling and pain, unsmooth lactation, swelling of lymph nodes on milk and the like.
(II) technical scheme
In order to achieve the above purpose, the invention is realized by the following technical scheme:
a traditional Chinese medicine composition for treating cow clinical mastitis, which comprises the following traditional Chinese medicine components: dandelion, astragalus, codonopsis pilosula, galangal, dried orange peel, glabrous greenbrier rhizome, raw malt, spina gleditsiae, liquorice and giant knotweed.
Preferably, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 30-60g of dandelion, 20-40g of astragalus, 20-40g of codonopsis pilosula, 10-30g of galangal, 10-30g of dried orange peel, 20-50g of glabrous greenbrier rhizome, 20-50g of raw malt, 30-60g of spina gleditsiae, 10-30g of liquorice and 20-40g of giant knotweed.
Preferably, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 40-55g of dandelion, 25-35g of astragalus, 25-35g of codonopsis pilosula, 15-25g of galangal, 15-25g of dried orange peel, 30-40g of glabrous greenbrier rhizome, 30-40g of raw malt, 40-55g of spina gleditsiae, 15-25g of liquorice and 25-35g of giant knotweed.
Preferably, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 50g of dandelion, 30g of astragalus, 25g of codonopsis pilosula, 20g of galangal, 18g of dried orange peel, 35g of glabrous greenbrier rhizome, 35g of raw malt, 50g of spina gleditsiae, 20g of liquorice and 30g of giant knotweed.
Further, the traditional Chinese medicine composition is used for preparing medicines for treating cow clinical mastitis; the traditional Chinese medicine composition is prepared into powder, granules, oral liquid or other pharmaceutically acceptable oral dosage forms by matching with pharmaceutically acceptable auxiliary materials according to a conventional pharmaceutical method in pharmacy.
Pharmacological actions of various traditional Chinese medicine components in the traditional Chinese medicine composition:
dandelion: bitter and sweet in taste, cold in nature, enters liver and stomach meridians; has effects of clearing heat and detoxicating, detumescence and resolving hard mass, promoting urination and treating stranguria; can be used for treating furuncle, acute mastitis, scrofula, conjunctival congestion, pharyngalgia, pulmonary abscess, appendicitis, jaundice due to damp-heat, and stranguria due to heat; the medicine contains flavonoid, coumarin, phenolic acid, terpene, sterol, polysaccharide and other effective components, and clinical research shows that the medicine has bacteriostasis, antioxidation, anti-inflammatory, antitumor, gastrointestinal protection and other pharmacological effects.
Radix astragali: sweet taste and slightly warm nature; spleen and lung meridian entered; has effects of invigorating qi, consolidating superficial resistance, expelling toxin, expelling pus, promoting urination, and promoting granulation. Can be used for treating qi deficiency, debilitation, chronic diarrhea, proctoptosis, spontaneous perspiration, edema, uterine prolapse, chronic nephritis, albuminuria, diabetes, and open sore.
Radix codonopsis pilosulae: sweet in taste, mild in nature, nontoxic, and enters spleen and lung meridians; has effects of invigorating spleen and stomach, invigorating qi, and promoting fluid production, and can be used for treating spleen and stomach weakness, deficiency of both qi and blood, tiredness, inappetence, thirst, chronic diarrhea, rectocele, etc. The radix codonopsis has the effects of enhancing immunity, dilating blood vessels, reducing blood pressure, improving microcirculation, enhancing hematopoiesis, and the like, and has the effect of enhancing the resistance of organisms.
Galangal: pungent taste and warm nature; spleen and stomach meridian; has effects in warming stomach, relieving vomiting, dispelling cold, and relieving pain; is mainly used for treating stomach cold pain, stomach cold vomiting, eructation, acid regurgitation and other diseases; the composition is mainly used for treating digestive tract diseases such as dyspepsia, acid regurgitation, emesis, gastric ulcer and the like. The modern researches have separated various effective pharmacological components from galangal, mainly volatile oil, flavonoid and diaryl heptanes, and have outstanding effects in resisting oxidation, resisting ulcer, inhibiting malignant proliferation of tumor, diminishing inflammation and relieving pain.
Dried orange peel: pungent and bitter in flavor, warm in nature, enter spleen and lung meridians; has effects of regulating qi-flowing, invigorating spleen, eliminating phlegm, and eliminating dampness; can be used for treating incoordination between spleen and stomach, emesis, cough, distention and inappetence; the pericarpium Citri Tangerinae mainly contains flavonoids, alkaloids, limonoids, volatile oils and microelements; has the pharmacological effects of inhibiting gastrointestinal smooth muscle, promoting secretion of digestive juice, promoting gallbladder function, relaxing bronchial smooth muscle, and resisting shock.
Rhizoma smilacis glabrae: sweet and light in taste and neutral in nature; enter liver and stomach meridians; has effects of removing toxic substances, removing dampness, and dredging joint; can be used for treating arthralgia and myalgia, damp-heat stranguria with turbid urine, leukorrhagia, carbuncle, scrofula, and scabies; the glabrous greenbrier rhizome mainly contains flavone, phenylpropanoid, steroid, organic acid, volatile oil and other components, and has obvious pharmacological activity in the aspects of anti-inflammatory, analgesic, cardiovascular system, immune system, tumor and the like.
Malt production: has effects of promoting qi circulation, resolving food stagnation, invigorating spleen, promoting appetite, removing milk and relieving distention, and can be used for treating dyspepsia, abdominal distention and pain, spleen deficiency, anorexia, galactostasis, and breast pain.
Spina gleditsiae: pungent taste and warm nature, enter liver and stomach meridians; has effects of detumescence, expelling pus, and killing parasite; mainly treats the initial stage of the carbuncle and the carbuncle or the suppuration without ulceration, externally treats the scabies, tinea and leprosy; spina Gleditsiae contains effective components such as flavone, lactone, coumarin or its glycosides, sterol, triterpenes, classification, organic acid, reducing sugar, triterpene saponin, etc.; has the pharmacological effects of resisting tumor, inhibiting bacteria, killing bacteria, resisting inflammation, resisting virus, regulating immunity, resisting allergy, resisting blood coagulation, resisting oxidation, reducing blood lipid, etc.
Licorice root: sweet in flavor, neutral in nature, and enters heart, lung, spleen and stomach meridians; has the effects of invigorating spleen, replenishing qi, clearing heat, detoxicating, eliminating phlegm, relieving cough, relieving spasm and pain, and harmonizing various medicines; can be used for treating weakness of spleen and stomach, listlessness, debilitation, palpitation, short breath, cough with excessive phlegm, abdominal pain, limb spasm, carbuncle, swelling, and sore toxin; can relieve toxicity and intensity of the medicine, and harmonize the efficacy of the traditional Chinese medicine components.
Giant knotweed rhizome: slightly bitter in taste and slightly cold in nature, enter liver, gall bladder and lung meridians; has effects of promoting diuresis, eliminating jaundice, clearing heat and detoxicating, removing blood stasis, relieving pain, relieving cough and eliminating phlegm; can be used for treating jaundice due to damp-heat, rheumatalgia, carbuncle, skin sore, and cough due to lung heat; the giant knotweed rhizome contains anthraquinone, resveratrol, polydatin, flavonoid and other chemical components, and modern pharmacology shows that the giant knotweed rhizome has the effects of regulating blood fat, resisting liver injury, shock, bacteria, cough, asthma, bacteria, virus, tumor and the like.
(III) beneficial effects
The invention provides a traditional Chinese medicine composition for treating cow clinical type mastitis and application thereof. The traditional Chinese medicine composition consists of dandelion, astragalus, dangshen, galangal, dried orange peel, glabrous greenbrier rhizome, raw malt, spina gleditsiae, liquorice and giant knotweed, and has the effects of detumescence and pain relief, heat clearing and detoxification, and ventilation and stagnation elimination. The traditional Chinese medicine composition has higher cure rate on cow clinical type mastitis, has obvious analgesic effect, has obvious relieving and eliminating effects on symptoms such as red swelling and pain, unsmooth milk discharge, swelling of lymph nodes on milk and the like, can effectively recover milk yield and milk quality of diseased cows, reduces the number of somatic cells of milk, and lightens or eliminates inflammation.
Detailed Description
For the purpose of making the objects, technical solutions and advantages of the embodiments of the present invention more apparent, the technical solutions in the embodiments of the present invention will be clearly and completely described in the following in conjunction with the embodiments of the present invention, and it is apparent that the described embodiments are some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Example 1
A traditional Chinese medicine composition for treating cow clinical mastitis comprises the following raw materials by weight: 60g of dandelion, 40g of astragalus, 40g of codonopsis pilosula, 30g of galangal, 30g of dried orange peel, 50g of glabrous greenbrier rhizome, 50g of raw malt, 60g of spina gleditsiae, 30g of liquorice and 40g of giant knotweed.
The traditional Chinese medicine composition is prepared into powder, granules, oral liquid or other pharmaceutically acceptable oral dosage forms by matching with pharmaceutically acceptable auxiliary materials according to a conventional pharmaceutical method in pharmacy.
Example 2
The difference between this example and example 1 is that the weight of the raw materials is: 30g of dandelion, 20g of astragalus, 20g of codonopsis pilosula, 10g of galangal, 10g of dried orange peel, 20g of glabrous greenbrier rhizome, 20g of raw malt, 30g of spina gleditsiae, 10g of liquorice and 20g of giant knotweed.
Example 3
The difference between this example and example 1 is that the weight of the raw materials is: 55g of dandelion, 35g of astragalus, 35g of codonopsis pilosula, 25g of galangal, 25g of dried orange peel, 40g of glabrous greenbrier rhizome, 40g of raw malt, 55g of spina gleditsiae, 25g of liquorice and 35g of giant knotweed.
Example 4
The difference between this example and example 1 is that the weight of the raw materials is: 40g of dandelion, 25g of astragalus, 25g of codonopsis pilosula, 15g of galangal, 15g of dried orange peel, 30g of glabrous greenbrier rhizome, 30g of raw malt, 40g of spina gleditsiae, 15g of liquorice and 25g of giant knotweed.
Example 5
The difference between this example and example 1 is that the weight of the raw materials is: 50g of dandelion, 30g of astragalus, 25g of codonopsis pilosula, 20g of galangal, 18g of dried orange peel, 35g of glabrous greenbrier rhizome, 35g of raw malt, 50g of spina gleditsiae, 20g of liquorice and 30g of giant knotweed.
Example 6
The difference between this example and example 1 is that the weight of the raw materials is: 36g of dandelion, 22g of astragalus, 22g of codonopsis pilosula, 12g of galangal, 12g of dried orange peel, 26g of glabrous greenbrier rhizome, 26g of raw malt, 34g of spina gleditsiae, 12g of liquorice and 22g of giant knotweed.
Example 7
The difference between this example and example 1 is that the weight of the raw materials is: 54g of dandelion, 36g of astragalus, 36g of codonopsis pilosula, 28g of galangal, 36g of dried orange peel, 44g of glabrous greenbrier rhizome, 44g of raw malt, 58g of spina gleditsiae, 28g of liquorice and 28g of giant knotweed.
Example 8
The difference between this example and example 1 is that the weight of the raw materials is: 48g of dandelion, 28g of astragalus, 30g of codonopsis pilosula, 16g of galangal, 20g of dried orange peel, 32g of glabrous greenbrier rhizome, 32g of raw malt, 45g of spina gleditsiae, 16g of liquorice and 28g of giant knotweed.
Example 9
The difference between this example and example 1 is that the weight of the raw materials is: 52g of dandelion, 33g of astragalus, 27g of codonopsis pilosula, 22g of galangal, 18g of dried orange peel, 36g of glabrous greenbrier rhizome, 32g of raw malt, 44g of spina gleditsiae, 18g of liquorice and 32g of giant knotweed.
Test example 1
Analgesic Effect test
1 materials and methods
1.1 extraction of Chinese herbs
Formula 1: 50g of dandelion, 30g of astragalus, 25g of codonopsis pilosula, 20g of galangal, 18g of dried orange peel, 35g of glabrous greenbrier rhizome, 35g of raw malt, 50g of spina gleditsiae, 20g of liquorice and 30g of giant knotweed.
And 2, a formula: 50g of dandelion, 30g of astragalus, 25g of codonopsis pilosula, 20g of galangal, 18g of dried orange peel, 35g of raw malt, 20g of liquorice.
And 3, formula 3: 50g of dandelion, 30g of astragalus, 25g of codonopsis pilosula, 35g of glabrous greenbrier rhizome, 50g of spina gleditsiae, 20g of liquorice and 30g of giant knotweed.
The raw materials of each formula are respectively weighed according to the formula, and are cleaned, dried and crushed to prepare the traditional Chinese medicine stock solution with the concentration of 1g/mL (1 g per milliliter equivalent to the original medicinal material) according to the conventional decoction method, and then the traditional Chinese medicine stock solution is sterilized and stored in a refrigerator at the temperature of 0-4 ℃ for standby.
1.2 test drug
The traditional Chinese medicine raw liquid of the formula 1-3, radix Angelicae sinensis, radix astragali, radix Rumicis Kangsan (radix astragali, radix Angelicae sinensis, herba Houttuyniae, spina Gleditsiae, herba Taraxaci, fructus Lipuidambaris, herba Violae, radix Isatidis, and pericarpium Citri Tangerinae), herba Taraxaci powder (herba Taraxaci, flos Lonicerae, fructus forsythiae, retinervus Luffae fructus, medulla Tetrapanacis, folium Hibisci Mutabilis, and Bulbus Fritillariae Thunbergii), and aspirin.
1.3 test animals
Healthy female Kunming mice 140, body weight (21+ -2) g.
1.4 methods and dosages of administration
Each 70 female kunming mice were divided into 7 groups, and a negative control group, a positive control group, a test 1 group, a test 2 group, a test 3 group, a control 1 group, a control 2 group. The administration methods are all gastric lavage administration, and the specific doses are shown in table 1.
TABLE 1 experiment group administration conditions of analgesic effect of the Chinese medicinal composition of the invention
1.5 test methods
1.5.1 Hot plate method analgesic test
The temperature of the water bath kettle is set to be (55+/-0.5 ℃), a large beaker of 1000mL is placed, 1 mouse is placed each time after the temperature is stable, the time from the contact of the mouse with the beaker to the licking of the foot and the pain threshold are recorded, if the mouse is not licked for 30 seconds, the mouse is discarded, the method is repeated for 2 times before the administration, and the average value measured for 2 times is taken as the initial pain threshold of the mouse. The 70 qualified mice were selected and randomly grouped, and the pain threshold of each mouse was measured at 20, 60 and 100 minutes after the last 1 dose of 7d following the dose of table 1, and 60s was recorded if the mice were 60s without licking.
1.5.2 acetic acid torsion test
The mice were randomly grouped into 10 groups, the mice were dosed once daily for 7 days according to the dose of Table 1, and after the administration for 1 hour on day 7, the mice of each group were injected with 0.7% acetic acid solution in the abdominal cavity at a weight of 0.1mL/10g, the number of writhing occurring in the mice within 5-25min after the drug injection was observed and recorded, and the pain suppression rate was calculated. Pain inhibition ratio= (average number of writhing in negative control group mice-average number of writhing in administration mice)/average number of writhing in negative control group mice x 100%.
1.6 data statistics and analysis
Experimental data were analyzed using GraphPad Prism 8.0 software two-way ANOVA, and the results were expressed as mean ± standard deviation, with significant differences expressed as (P < 0.05).
2 results and analysis
2.1 Hot plate method analgesic test
As can be seen from table 2, there was no significant difference in pain threshold (P > 0.05) between groups of mice prior to dosing; after 20min following dosing, the pain threshold of mice in each dosing group was significantly higher than that of the negative control group, the difference was significant (P < 0.05), wherein the pain threshold of mice in trial 1 group was significantly higher than that of positive control group and trial 2-3, control 1-2 groups (P < 0.05); the pain threshold of mice in each of the dosing groups was still significantly higher than that of the negative control group (P < 0.05) at 60min and 100min after dosing, with mice in trial 1 still significantly higher than that of the positive control group and trial 2-3, control 1-2 groups (P < 0.05).
Table 2 pain threshold results(s) for groups of mice
| Group of | Before administration of the drug | 20min after administration | 60min after administration | 100min after administration |
| Negative control group | 14.1±2.03 | 14.4±2.37 a | 13.9±2.03 a | 14.1±2.33 a |
| Positive control group | 14.3±2.06 | 18.5±2.17 b | 19.7±2.45 b | 20.4±1.78 b |
| Test 1 group | 14.2±2.10 | 26.5±2.12 c | 25.4±1.17 c | 23.9±1.79 c |
| Test 2 groups | 14.5±1.72 | 17.3±1.34 bd | 17.1±2.23 b | 17.0±1.25 d |
| Test 3 groups | 14.0±2.79 | 19.4±2.55 b | 18.9±1.85 b | 17.3±1.16 d |
| Control group 1 | 14.6±2.37 | 21.0±2.45 be | 19.6±1.65 b | 18.4±1.43 d |
| Control group 2 | 14.2±1.93 | 20.9±2.28 be | 18.8±1.93 b | 18.9±1.66 d |
Note that: the same column of data shoulder mark lower case letters differ significantly (P < 0.05); the inclusion of the same lower case letter or no letter indicates that the difference is not significant (P > 0.05).
2.2 acetic acid torsion test
As can be seen from table 3, the number of twists of mice in each of the administration groups was significantly lower than that of the negative control group (P < 0.05); wherein the number of writhing times of the mice in the test 1 group is significantly lower than that of the mice in the test 2-3 group and the control 1-2 group (P < 0.05), and there is no significant difference (P > 0.05) compared with the positive control group; the pain inhibition rate of test 1 group was 58.18% significantly higher than positive control group, test 2-3 group and control 1-2 group.
Table 3 acetic acid torsion test results for mice of each group
| Group of | Number of times of twisting body | Pain inhibition rate/% |
| Negative control group | 60.5±5.08 a | |
| Positive control group | 26.2±1.48 b | 56.69 |
| Test 1 group | 25.3±1.78 b | 58.18 |
| Test 2 groups | 38.4±2.76 c | 36.53 |
| Test 3 groups | 34.3±1.77 d | 43.31 |
| Control group 1 | 31.4±2.22 d | 48.10 |
| Control group 2 | 30.4±2.07 d | 49.75 |
Note that: the same column of data shoulder mark lower case letters differ significantly (P < 0.05); the inclusion of the same lower case letter or no letter indicates that the difference is not significant (P > 0.05).
Conclusion 3
The test results show that the different traditional Chinese medicine compositions have certain analgesic effect. Compared with classical formulas of Guiqi Rukang powder and dandelion powder, the traditional Chinese medicine composition has better analgesic effect on mice; when the traditional Chinese medicine composition lacks galangal, dried orange peel, raw malt or spina gleditsiae, polygonum cuspidatum and glabrous greenbrier rhizome, the analgesic effect of the traditional Chinese medicine composition on mice is obviously weakened, the traditional Chinese medicine composition is reasonably compatible by applying the dialectical treatment principle of traditional Chinese medicine, the synergistic effect among medicinal materials is fully exerted, and the ingredients in the formula are indispensable.
Test example 2
1 materials and methods
1.1 test animals and groups
80 Holstein cows with clinical mastitis are selected from a Ningxia Wu Zhongmou farm, the treatment is not carried out before the test, and the 80 sick cows are randomly divided into 4 groups respectively including a test group, a control group 1, a control group 2 and a control group 3 according to a single factor test design principle, and 20 cows in each group. Meanwhile, 20 healthy Holstein cows are selected as a blank control group.
Before the test, the test site, the cultivation equipment and the like are sterilized, and then the test is performed. During the test period, the test cows are fed with the total mixed ration, and the cows eat and drink water freely. Each group of test cows are fed in a limited manner in the same place. Other daily management procedures such as immunization, insect expelling and the like are carried out according to the conventional management of a dairy farm.
1.2 methods of treatment
The specific administration methods of each group are shown in Table 4.
Table 4 methods of administration of each group
1.3 detection index and detection method
(1) Determination of therapeutic effect of mastitis
And (3) curing: the inflamed parts of the dairy cows are recovered to be normal, the breast lumps completely disappear, the inflammatory reactions such as red, swelling, heat, pain and the like are avoided, the recurrence phenomenon is avoided, the clots and floccules in the milk disappear, and the color and the yield of the milk are recovered to be normal.
The method is effective: the inflammation such as red, swelling, heat and pain of the dairy cow breast is relieved, the fever symptoms and pain response of the dairy cow body are obviously relieved, the mental state of the dairy cow is improved, the appetite is restored, and the milk yield is obviously increased compared with that before treatment.
Invalidation: the symptom of cow mastitis is not reduced, even aggravated, the milk yield is further reduced or the milk production is stopped, and the appetite of the cow is abolished.
(2) Milk yield and somatic cell count
Daily milk production of each group of cows is recorded during the test period; and about 100g milk samples are collected from 10 cows randomly selected in each group of the early, middle and late days 1 and 3 days before the end of the test, and the early, middle and late milk samples are uniformly mixed for detecting the somatic cell number in the milk.
1.4 data statistics and analysis
Experimental data were analyzed using GraphPad Prism 8.0 software two-way ANOVA, and the results were expressed as mean ± standard deviation, with significant differences expressed as (P < 0.05).
2 results
2.1 treatment effects of groups on clinical mastitis cows
As can be seen from table 5, the therapeutic drugs used in each group have a certain therapeutic effect on clinical mastitis of cows; the disease of the dairy cows in the test group is cured by using the traditional Chinese medicine composition, the disease condition of the dairy cows is obviously improved, the total effective rate of treatment reaches 100%, the treatment effect is obviously higher than that of classical formulas of Guiqi Rukangsan and Dandelion powder, and the treatment effect is also obviously higher than that of western medicines.
Table 5 treatment effects of groups on clinical mastitis cows
2.2 effects of groups on milk yield and somatic cell count in cows with clinical mastitis
As can be seen from table 6, the milk yield of the dairy cows in the test group and the control groups 1 to 3 on the first day of treatment is significantly lower than that of the blank control group, the number of somatic cells in the milk is significantly higher than that of the blank control group, and the difference is significant (P < 0.05); after 14 days of treatment, the milk yield of the test group and the control 1-3 groups is obviously increased compared with the first day of treatment, wherein the milk yield of the test group is increased most, and the difference between the test group and the blank control group is not obvious (P is more than 0.05); after 14 days of treatment, the number of somatic cells in the milk of the test group and the control 1-3 groups is obviously reduced compared with the first day, wherein the reduction amplitude of the number of somatic cells in the milk of the test group is maximum, and the difference between the test group and the blank control group is not obvious (P is more than 0.05).
Table 6 influence of groups on milk yield and somatic cell count of cows with clinical mastitis
Note that: the same column of data shoulder mark lower case letters differ significantly (P < 0.05); the inclusion of the same lower case letter or no letter indicates that the difference is not significant (P > 0.05).
Conclusion 3
Compared with classical Chinese medicinal formulas and western medicines, the Chinese medicinal composition has higher cure rate on clinical mastitis of cows, can effectively relieve or eliminate inflammation symptoms such as red, swelling, heat, pain and the like of the sick cows, can effectively recover milk yield and milk quality, reduces the number of somatic cells of the milk, and reduces or eliminates inflammation.
The above embodiments are only for illustrating the technical solution of the present invention, and are not limiting; although the invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical scheme described in the foregoing embodiments can be modified or some technical features thereof can be replaced by equivalents; such modifications and substitutions do not depart from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims (6)
1. The traditional Chinese medicine composition for treating cow clinical mastitis is characterized by comprising the following traditional Chinese medicine components: dandelion, astragalus, codonopsis pilosula, galangal, dried orange peel, glabrous greenbrier rhizome, raw malt, spina gleditsiae, liquorice and giant knotweed.
2. The traditional Chinese medicine composition for treating cow clinical mastitis according to claim 1, wherein the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 30-60g of dandelion, 20-40g of astragalus, 20-40g of codonopsis pilosula, 10-30g of galangal, 10-30g of dried orange peel, 20-50g of glabrous greenbrier rhizome, 20-50g of raw malt, 30-60g of spina gleditsiae, 10-30g of liquorice and 20-40g of giant knotweed.
3. The traditional Chinese medicine composition for treating cow clinical mastitis according to claim 1, wherein the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 40-55g of dandelion, 25-35g of astragalus, 25-35g of codonopsis pilosula, 15-25g of galangal, 15-25g of dried orange peel, 30-40g of glabrous greenbrier rhizome, 30-40g of raw malt, 40-55g of spina gleditsiae, 15-25g of liquorice and 25-35g of giant knotweed.
4. The traditional Chinese medicine composition for treating cow clinical mastitis according to claim 1, wherein the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 50g of dandelion, 30g of astragalus, 25g of codonopsis pilosula, 20g of galangal, 18g of dried orange peel, 35g of glabrous greenbrier rhizome, 35g of raw malt, 50g of spina gleditsiae, 20g of liquorice and 30g of giant knotweed.
5. The traditional Chinese medicine composition for treating cow clinical mastitis according to claim 1, wherein the traditional Chinese medicine composition is prepared into powder, granules, oral liquid or other pharmaceutically acceptable oral dosage forms according to a conventional pharmaceutical method in pharmacy and with pharmaceutically acceptable auxiliary materials.
6. Use of a combination of traditional Chinese medicines according to any one of claims 1 to 4 for the treatment of cow clinical mastitis, wherein the traditional Chinese medicine composition is used for the preparation of a medicament for the treatment of cow clinical mastitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310394287.XA CN116509969A (en) | 2023-04-13 | 2023-04-13 | Traditional Chinese medicine composition for treating cow clinical type mastitis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310394287.XA CN116509969A (en) | 2023-04-13 | 2023-04-13 | Traditional Chinese medicine composition for treating cow clinical type mastitis and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116509969A true CN116509969A (en) | 2023-08-01 |
Family
ID=87393240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310394287.XA Pending CN116509969A (en) | 2023-04-13 | 2023-04-13 | Traditional Chinese medicine composition for treating cow clinical type mastitis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116509969A (en) |
-
2023
- 2023-04-13 CN CN202310394287.XA patent/CN116509969A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104012798B (en) | Be used for the treatment of the feed of Gilt Uterus intimitis, Chinese medicine composition and preparation method | |
| CN105166544A (en) | Pig mixed feed and preparation method thereof | |
| CN102772781A (en) | Traditional Chinese medicine preparation for treating chronic colitis and preparation method thereof | |
| CN103239662B (en) | Parasite expelling Chinese herbal preparation for animals | |
| CN102847021B (en) | Enema for treating ulcerative colitis and preparation method thereof | |
| CN104436131A (en) | Pharmaceutical composition used for treating swine dysentery and preparation method of pharamceutical composition | |
| CN102846864A (en) | Chinese herbal veterinary medicine for preventing and treating swine infectious atrophic rhinitis and preparation process thereof | |
| TW202330006A (en) | Composition for preventing, improving or alleviating symptoms relating to qi deficiency and/or blood deficiency | |
| CN102198261B (en) | Chinese medicinal preparation for treating elder chronic colitis and preparation method thereof | |
| CN104825960A (en) | Traditional Chinese medicine for treating pulmonary tuberculosis and preparation method thereof | |
| CN104524174A (en) | Traditional Chinese medicine composition for treating rheumatic arthralgia and preparation method thereof | |
| CN104547902A (en) | Application of traditional Chinese preparation in preparation of drugs used for treating chronic enteritis and appendicitis | |
| CN107823375A (en) | A kind of Chinese medicinal tablet for treating mastitis for milk cows and preparation method thereof | |
| CN103463449A (en) | Traditional Chinese medicine composite used for treating haemorrhoids and preparation method and application thereof | |
| CN103007145B (en) | Traditional Chinese medicine composition for treating children rotavirus enteritis and preparation method of composition | |
| CN116509969A (en) | Traditional Chinese medicine composition for treating cow clinical type mastitis and application thereof | |
| CN104887950A (en) | Mastitis treatment traditional Chinese medicine compound | |
| CN103432416B (en) | Chinese herba preparation for treating children iron-deficiency anemia and preparation method thereof | |
| CN104666468A (en) | Pharmaceutical composition for treating hyperthyroidism and scrofula | |
| CN105267684A (en) | Traditional Chinese medicine for treating chemotherapeutic phlebitis of tumor patients and preparation method thereof | |
| CN104998189A (en) | Traditional Chinese medicine powder for treating infantile oral ulcer of wind-heat spleen type and preparation method thereof | |
| CN105031065A (en) | Traditional Chinese medicine for treating acute suppurative otitis media and preparation method of traditional Chinese medicine | |
| CN115227787A (en) | Traditional Chinese medicine composition for treating acute tonsillitis and application thereof | |
| CN104825980A (en) | Traditional Chinese medicine preparation for treating diarrhea | |
| CN104587256A (en) | Traditional Chinese medicine composition for treating prostatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |